AI assistant
Aprea Therapeutics, Inc. — Director's Dealing 2021
Oct 5, 2021
35269_dirs_2021-10-05_e79c3f28-8af6-419f-8a8f-d9af0c636367.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Aprea Therapeutics, Inc. (APRE)
CIK: 0001781983
Period of Report: 2021-10-01
Reporting Person: Korbel Gregory Alan (SVP, Chief Business Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-10-01 | Common Stock | M | 27500 | $0.92 | Acquired | 44667 | Direct |
| 2021-10-01 | Common Stock | S | 27500 | $4.89 | Disposed | 17167 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-10-01 | Stock Option (right to Buy) | $0.92 | M | 27500 | Disposed | 2026-09-14 | Common Stock (27500) | Direct |
Footnotes
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.80 to $5.06 inclusive. The reporting person undertakes to provide Aprea Therapeutics, Inc., any security holder of Aprea Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: This option was granted on September 14, 2016 and is fully exercisable.